A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

Annals of Oncology

Volumn 12, Issue 5, 2001, Pages 605-614

  Villalona Calero, M A ^a,b   Blum, J L ^c   Jones, S E ^c   Diab, S ^b   Elledge, R ^b   Khoury, P ^b   Von Hoff, D ^b   Kraynak, M ^a   Moczygemba, J ^a   Kromelis, P ^c   Griffin, T ^d   Rowinsky, E K ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

5 FU; Breast; Capecitabine; Pharmacokinetics; Taxol; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; CASTOR OIL; CREMOPHOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG METABOLITE; FLUOROURACIL; LOSOXANTRONE; METHOTREXATE; PACLITAXEL;

ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG INFUSION; EDEMA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034986988     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011181010669     Document Type: Article

References (27)

1. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
2. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
3. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
4. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
5. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors
6. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
7. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine)
8. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
9. Preliminary Studies of a novel oral fluoropyrimidine carbamate: Capecitabine
10. A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors
11. TM in colorectal cancer patients
12. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/taxotere in human cancer xenografts
13. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
14. Taxol, a microtubule stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages
15. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
16. Taxol metabolism by human liver microsomes: Identification of cytochrome p450 isoenzymes involved in its biotransformation
17. Paclitaxel metabolites in human plasma and urine. Identification of 6 alpha-hydroxytaxol, 7 epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry
18. Effects of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
19. Noncompartmental analysis based on statistical moment theory
20. A phase I and pharmacokinetics study of the combination of capecitabine and docetaxel in patients with advanced solid tumors
21. Paclitaxel (Taxol)
22. Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan
23. Paclitaxel activity in anthracycline refractory breast cancer patients
24. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European cancer center trial
25. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
26. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism